Sucampo Pharmaceuticals' (SCMP) "Neutral" Rating Reiterated at Mizuho

Ratings analysis reveals 67% of Sucampo Pharma's analysts are positive. The rating was reinitiated by TH Capital with "Buy" on Thursday, October 29. The stock of Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 1st. (NASDAQ:CHRS) rating on Monday, November 23.

Ameriprise Financial Inc. lifted its holdings in Sucampo Pharmaceuticals, Inc. UBS has "Hold" rating and $18.0 target.

Additionally, according to the most recent 13F filing from Sucampo Pharmaceuticals, Inc. On Wednesday, September 27 the stock rating was maintained by Credit Suisse with "Buy". The stock traded within a range of $18.00 and $18.75. The company was initiated on Friday, October 9 by Mizuho. Jefferies has "Hold" rating and $1100 target. Nationwide Fund Advsrs invested 0% in Sucampo Pharmaceuticals, Inc. The stock of Coherus Biosciences, Inc. (NASDAQ:SNDX) is a huge mover today! Leerink Swann now has a $15.00 price target on the biopharmaceutical company's stock. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.09% since January 12, 2017 and is uptrending. It was reported on Jan, 12 by Barchart.com. Company insiders own 3.31% of the company's stock.

In other news, CFO Andrew P. Smith sold 1,766 shares of the business's stock in a transaction on Tuesday, November 15th. The company had Year Ago Sales of 73.02 Million. Shares for $12.00M were sold by Kuno Sachiko.

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The company has market cap of $862.55 million. The company operates in the Healthcare sector with a market capitalization of 862960. It now has negative earnings. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. Advisor Group Inc. now owns 20,475 shares of the biopharmaceutical company's stock worth $242,000 after purchasing an additional 6,361 shares during the last quarter. About 797,743 shares traded. SG Americas Securities LLC lifted its position in shares of Sucampo Pharmaceuticals by 5.6% in the second quarter. It has underperformed by 22.00% the S&P500.

Investors sentiment increased to 1.26 in 2017 Q3. Its up 0.32, from 1.33 in 2017Q2. 31 funds opened positions while 58 raised stakes. Ahl Ptnrs Llp reported 11,653 shares. Its up 2.14% from 4.59 million shares previously.

Analysts' mean recommendation for Sucampo Pharmaceuticals, Inc. Investors who are keeping close eye on the stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:CHRS) or 62,553 shares. Goldman Sachs has invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. Piermont Capital, a Missouri-based fund reported 178,570 shares. Fifth Third Bancshares holds 41,752 shares. Comml Bank Of America De holds 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 32,964 shares. Krensavage Asset Management Lc has invested 10.42% in Sucampo Pharmaceuticals, Inc. In terms of efficiency, SCMP has an asset turnover ratio of 0.56.

Analysts await CRA International, Inc. (NASDAQ:SNDX) to report earnings on March, 1. According to the Analysts, the Low Earnings estimate for the current quarter is $0.15, while the High earnings estimate is $0.26.Comparatively, EPS for the same quarter a year ago was $0.03. (NASDAQ:SCMP). Prelude Mngmt Ltd Liability Com reported 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. Finally, SGYP's beta of 1.24 indicates that the stock has an above average level of market risk. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Altre Notizie